P
Philip D. Greenberg
Researcher at Fred Hutchinson Cancer Research Center
Publications - 277
Citations - 27015
Philip D. Greenberg is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Cytotoxic T cell & T cell. The author has an hindex of 79, co-authored 263 publications receiving 24330 citations. Previous affiliations of Philip D. Greenberg include Washington University in St. Louis & Bristol-Myers Squibb.
Papers
More filters
Journal ArticleDOI
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.
Stanley R. Riddell,Kathe S. Watanabe,James M. Goodrich,Cheng R. Li,Mounzer E. Agha,Philip D. Greenberg,Philip D. Greenberg +6 more
TL;DR: Cytomegalovirus-specific CD8+ cytotoxic T cell (CTL) clones could be isolated from bone marrow donors, propagated in vitro, and adoptively transferred to immunodeficient bone marrow transplant recipients and no toxicity developed and the clones provided persistent reconstitution of CD8+.
Journal ArticleDOI
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.
Peter P. Lee,Cassian Yee,Peter A. Savage,Lawrence Fong,Dirk G. Brockstedt,Jeffrey S. Weber,Denise L. Johnson,Susan M. Swetter,John A. Thompson,Philip D. Greenberg,Mario Roederer,Mark M. Davis +11 more
TL;DR: It is demonstrated that systemic TAA-specific T-cell responses can develop de novo in cancer patients, but that antigen-specific unresponsiveness may explain why such cells are unable to control tumor growth.
Journal ArticleDOI
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.
Marc A. Gavin,Troy R. Torgerson,Evan G. Houston,Paul deRoos,William Y. Ho,Asbjørg Stray-Pedersen,Elizabeth L. Ocheltree,Philip D. Greenberg,Hans D. Ochs,Alexander Y. Rudensky +9 more
TL;DR: Forkhead winged-helix transcription factor Foxp3 serves as the dedicated mediator of the genetic program governing CD25+CD4+ regulatory T cell (T(R)) development and function in mice and the relationship between FOXP3 expression and human T(R) development is addressed.
Journal ArticleDOI
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
Brian G. Till,Brian G. Till,Michael C. Jensen,Jinjuan Wang,Eric Y. Chen,Brent L. Wood,Harvey A. Greisman,Xiaojun Qian,Scott E. James,Andrew Raubitschek,Stephen J. Forman,Ajay K. Gopal,Ajay K. Gopal,John M. Pagel,John M. Pagel,Catherine G. Lindgren,Philip D. Greenberg,Philip D. Greenberg,Stanley R. Riddell,Stanley R. Riddell,Oliver W. Press,Oliver W. Press +21 more
TL;DR: The results of a proof-of-concept clinical trial in which patients with relapsed or refractory indolent B-cell lymphoma or mantle cell lymphoma were treated with autologous T cells genetically modified by electroporation with a vector plasmid encoding a CD20-specific chimeric T- cell receptor and neomycin resistance gene show the safety, feasibility, and potential antitumor activity of adoptive T-cell therapy using this approach.
Journal ArticleDOI
Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.
TL;DR: It is demonstrated that restoration of CMV-specific CTL responses may require an extended time period after BMT in some patients, and that such patients are at increased risk of developing severe CMV disease.